Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pembrolizumab + eftilagimod alfa
- Development stage
- Unknown
- Lead developer
- Immutep
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
A combination therapy consisting of pembrolizumab, a PD-1 checkpoint inhibitor, and eftilagimod alfa, a soluble LAG-3 protein and MHC Class II agonist. This combination is being evaluated in the EFTISARC-NEO Phase II trial, led by the Maria Sklodowska-Curie National Research Institute of Oncology, as a neoadjuvant treatment for resectable, non-metastatic soft tissue sarcoma in conjunction with radiotherapy. Eftilagimod alfa acts as an antigen-presenting cell (APC) activator, binding to MHC Class II molecules to trigger the activation of CD8+ and CD4+ T cells, dendritic cells, NK cells, and monocytes, thereby enhancing the anti-tumor immune response initiated by pembrolizumab's blockade of the PD-1/PD-L1 pathway.
- Brand names
- Keytruda
- Other names
- eftilagimod alfaeftipembrolizumab
02
Targets
MHC II (Major histocompatibility complex class II receptor)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on pembrolizumab + eftilagimod alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pembrolizumab + eftilagimod alfa.